Do analysts recommend AVCT or BVXP?

Avacta Group presently has a consensus price target of GBX 99, indicating a potential upside of 25.32%. Given Avacta Group's stronger consensus rating and higher possible upside, research analysts plainly believe Avacta Group is more favorable than Bioventix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avacta Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Bioventix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, AVCT or BVXP?

Bioventix has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avacta Group £113K 3,181.74 -£30.08M -£9.66 N/A Bioventix £12.54M 7.03 £8.12M £140.52 12.01

Is AVCT or BVXP more profitable?

Bioventix has a net margin of 59.30% compared to Avacta Group's net margin of -33,961.06%. Bioventix's return on equity of 65.83% beat Avacta Group's return on equity. Company Net Margins Return on Equity Return on Assets Avacta Group -33,961.06% -2,929.47% -21.80% Bioventix 59.30% 65.83% 54.07%

Do analysts rate PRTC or BVXP?

PureTech Health presently has a consensus target price of GBX 508, indicating a potential upside of 287.20%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts clearly believe PureTech Health is more favorable than Bioventix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Bioventix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, PRTC or BVXP?

Bioventix has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health £4.66M 68.55 -£91.86M -£46.00 N/A Bioventix £12.54M 7.03 £8.12M £140.52 12.01

Which has better earnings & valuation, BVXP or SCLP?

Bioventix has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventix £12.54M 7.03 £8.12M £140.52 12.01 Scancell £4.71M 40.53 -£6.75M -£0.55 N/A

Is BVXP or SCLP more profitable?

Bioventix has a net margin of 59.30% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Bioventix's return on equity. Company Net Margins Return on Equity Return on Assets Bioventix 59.30% 65.83% 54.07% Scancell -116.98% 90.29% -45.28%

Does the media prefer BVXP or SCLP?

In the previous week, Bioventix had 1 more articles in the media than Scancell. MarketBeat recorded 2 mentions for Bioventix and 1 mentions for Scancell. Bioventix's average media sentiment score of 1.27 beat Scancell's score of 0.00 indicating that Bioventix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventix 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scancell 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Bioventix (BVXP) Competitors

GBX 1,688 +13.00 (+0.78%)

As of 10:07 AM Eastern

Compare

BVXP vs. AVCT, PRTC, HZD, VRP, and SCLP

Should you buy Bioventix stock or one of its competitors? MarketBeat compares Bioventix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bioventix include Avacta Group (AVCT), PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), and Scancell (SCLP). These companies are all part of the "biotechnology" industry.

How does Bioventix compare to Avacta Group?

Avacta Group (LON:AVCT) and Bioventix (LON:BVXP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

2.9% of Avacta Group shares are held by institutional investors. Comparatively, 20.6% of Bioventix shares are held by institutional investors. 49.1% of Avacta Group shares are held by company insiders. Comparatively, 6.2% of Bioventix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Bioventix has a net margin of 59.30% compared to Avacta Group's net margin of -33,961.06%. Bioventix's return on equity of 65.83% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avacta Group	-33,961.06%	-2,929.47%	-21.80%
Bioventix	59.30%	65.83%	54.07%

Bioventix has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avacta Group	£113K	3,181.74	-£30.08M	-£9.66	N/A
Bioventix	£12.54M	7.03	£8.12M	£140.52	12.01

Avacta Group presently has a consensus price target of GBX 99, indicating a potential upside of 25.32%. Given Avacta Group's stronger consensus rating and higher possible upside, research analysts plainly believe Avacta Group is more favorable than Bioventix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Bioventix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Avacta Group has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Bioventix has a beta of 0.554, indicating that its stock price is 45% less volatile than the broader market.

In the previous week, Bioventix had 2 more articles in the media than Avacta Group. MarketBeat recorded 2 mentions for Bioventix and 0 mentions for Avacta Group. Bioventix's average media sentiment score of 1.27 beat Avacta Group's score of 0.00 indicating that Bioventix is being referred to more favorably in the news media.

Company	Overall Sentiment
Avacta Group	Neutral
Bioventix	Positive

Summary

Bioventix beats Avacta Group on 10 of the 16 factors compared between the two stocks.

How does Bioventix compare to PureTech Health?

PureTech Health (LON:PRTC) and Bioventix (LON:BVXP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

34.0% of PureTech Health shares are held by institutional investors. Comparatively, 20.6% of Bioventix shares are held by institutional investors. 13.3% of PureTech Health shares are held by company insiders. Comparatively, 6.2% of Bioventix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

PureTech Health has a beta of 0.811, indicating that its share price is 19% less volatile than the broader market. Comparatively, Bioventix has a beta of 0.554, indicating that its share price is 45% less volatile than the broader market.

PureTech Health presently has a consensus target price of GBX 508, indicating a potential upside of 287.20%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts clearly believe PureTech Health is more favorable than Bioventix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Bioventix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Bioventix has a net margin of 59.30% compared to PureTech Health's net margin of -2,355.32%. Bioventix's return on equity of 65.83% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Bioventix	59.30%	65.83%	54.07%

In the previous week, Bioventix had 2 more articles in the media than PureTech Health. MarketBeat recorded 2 mentions for Bioventix and 0 mentions for PureTech Health. Bioventix's average media sentiment score of 1.27 beat PureTech Health's score of 0.00 indicating that Bioventix is being referred to more favorably in the news media.

Company	Overall Sentiment
PureTech Health	Neutral
Bioventix	Positive

Bioventix has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	68.55	-£91.86M	-£46.00	N/A
Bioventix	£12.54M	7.03	£8.12M	£140.52	12.01

Summary

Bioventix beats PureTech Health on 9 of the 16 factors compared between the two stocks.

How does Bioventix compare to Horizon Discovery Group plc (HZD.L)?

Bioventix (LON:BVXP) and Horizon Discovery Group plc (HZD.L) (LON:HZD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

Bioventix has higher earnings, but lower revenue than Horizon Discovery Group plc (HZD.L). Horizon Discovery Group plc (HZD.L) is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventix	£12.54M	7.03	£8.12M	£140.52	12.01
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A

In the previous week, Bioventix had 2 more articles in the media than Horizon Discovery Group plc (HZD.L). MarketBeat recorded 2 mentions for Bioventix and 0 mentions for Horizon Discovery Group plc (HZD.L). Bioventix's average media sentiment score of 1.27 beat Horizon Discovery Group plc (HZD.L)'s score of 0.00 indicating that Bioventix is being referred to more favorably in the media.

Company	Overall Sentiment
Bioventix	Positive
Horizon Discovery Group plc (HZD.L)	Neutral

20.6% of Bioventix shares are owned by institutional investors. 6.2% of Bioventix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Bioventix has a net margin of 59.30% compared to Horizon Discovery Group plc (HZD.L)'s net margin of 0.00%. Bioventix's return on equity of 65.83% beat Horizon Discovery Group plc (HZD.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventix	59.30%	65.83%	54.07%
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A

Summary

Bioventix beats Horizon Discovery Group plc (HZD.L) on 9 of the 10 factors compared between the two stocks.

How does Bioventix compare to Verona Pharma plc (VRP.L)?

Bioventix (LON:BVXP) and Verona Pharma plc (VRP.L) (LON:VRP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

20.6% of Bioventix shares are held by institutional investors. 6.2% of Bioventix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Bioventix had 2 more articles in the media than Verona Pharma plc (VRP.L). MarketBeat recorded 2 mentions for Bioventix and 0 mentions for Verona Pharma plc (VRP.L). Bioventix's average media sentiment score of 1.27 beat Verona Pharma plc (VRP.L)'s score of 0.00 indicating that Bioventix is being referred to more favorably in the media.

Company	Overall Sentiment
Bioventix	Positive
Verona Pharma plc (VRP.L)	Neutral

Bioventix has a net margin of 59.30% compared to Verona Pharma plc (VRP.L)'s net margin of 0.00%. Bioventix's return on equity of 65.83% beat Verona Pharma plc (VRP.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventix	59.30%	65.83%	54.07%
Verona Pharma plc (VRP.L)	N/A	N/A	N/A

Bioventix has higher revenue and earnings than Verona Pharma plc (VRP.L). Verona Pharma plc (VRP.L) is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventix	£12.54M	7.03	£8.12M	£140.52	12.01
Verona Pharma plc (VRP.L)	N/A	N/A	N/A	-£32.70	N/A

Summary

Bioventix beats Verona Pharma plc (VRP.L) on 10 of the 10 factors compared between the two stocks.

How does Bioventix compare to Scancell?

Bioventix (LON:BVXP) and Scancell (LON:SCLP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Bioventix has a net margin of 59.30% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Bioventix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventix	59.30%	65.83%	54.07%
Scancell	-116.98%	90.29%	-45.28%

In the previous week, Bioventix had 1 more articles in the media than Scancell. MarketBeat recorded 2 mentions for Bioventix and 1 mentions for Scancell. Bioventix's average media sentiment score of 1.27 beat Scancell's score of 0.00 indicating that Bioventix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventix	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scancell	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bioventix has a beta of 0.554, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Scancell has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market.

20.6% of Bioventix shares are owned by institutional investors. Comparatively, 1.5% of Scancell shares are owned by institutional investors. 6.2% of Bioventix shares are owned by insiders. Comparatively, 15.5% of Scancell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Bioventix has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventix	£12.54M	7.03	£8.12M	£140.52	12.01
Scancell	£4.71M	40.53	-£6.75M	-£0.55	N/A

Summary

Bioventix beats Scancell on 9 of the 13 factors compared between the two stocks.

Get Bioventix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BVXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BVXP vs. The Competition

Export

Metric	Bioventix	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£88.20M	£497.09M	£6.81B	£2.77B
Dividend Yield	8.57%	3.86%	2.68%	6.16%
P/E Ratio	12.01	3.18	25.79	366.66
Price / Sales	7.03	7,182.40	548.63	85,978.63
Price / Cash	30.89	13.13	46.33	27.87
Price / Book	7.34	88.54	10.77	7.76
Net Income	£8.12M	-£96.07M	£3.57B	£5.89B
7 Day Performance	-3.27%	1.88%	3.15%	-0.71%
1 Month Performance	-0.71%	0.72%	2.34%	-1.20%
1 Year Performance	-38.62%	71.74%	33.41%	65.93%

Bioventix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BVXP Bioventix	N/A	GBX 1,688 +0.8%	N/A	-36.4%	£88.20M	£12.54M	12.01	12	News Coverage Positive News Insider Trade
AVCT Avacta Group	N/A	GBX 73.65 +0.2%	GBX 99 +34.4%	+146.1%	£335.19M	£113K	N/A	120
PRTC PureTech Health	1.3368 of 5 stars	GBX 131.40 +1.1%	GBX 508 +286.6%	+5.8%	£319.85M	£4.66M	N/A	300
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416
VRP Verona Pharma plc (VRP.L)	N/A	N/A	N/A	N/A	£228M	N/A	N/A	22	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:BVXP) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bioventix (BVXP) Competitors

BVXP vs. AVCT, PRTC, HZD, VRP, and SCLP

How does Bioventix compare to Avacta Group?

Summary

How does Bioventix compare to PureTech Health?

Summary

How does Bioventix compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does Bioventix compare to Verona Pharma plc (VRP.L)?

Summary

How does Bioventix compare to Scancell?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVXP vs. The Competition

Bioventix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bioventix (BVXP) Competitors

BVXP vs. AVCT, PRTC, HZD, VRP, and SCLP

How does Bioventix compare to Avacta Group?

Do institutionals and insiders believe in AVCT or BVXP?

Is AVCT or BVXP more profitable?

Which has preferable earnings and valuation, AVCT or BVXP?

Do analysts recommend AVCT or BVXP?

Which has more risk & volatility, AVCT or BVXP?

Does the media refer more to AVCT or BVXP?

Summary

How does Bioventix compare to PureTech Health?

Do institutionals & insiders believe in PRTC or BVXP?

Which has more volatility and risk, PRTC or BVXP?

Do analysts rate PRTC or BVXP?

Is PRTC or BVXP more profitable?

Does the media favor PRTC or BVXP?

Which has better valuation & earnings, PRTC or BVXP?

Summary

How does Bioventix compare to Horizon Discovery Group plc (HZD.L)?

Which has stronger earnings & valuation, BVXP or HZD?

Does the media refer more to BVXP or HZD?

Do insiders and institutionals hold more shares of BVXP or HZD?

Is BVXP or HZD more profitable?

Summary

How does Bioventix compare to Verona Pharma plc (VRP.L)?

Do insiders and institutionals have more ownership in BVXP or VRP?

Does the media favor BVXP or VRP?

Is BVXP or VRP more profitable?

Which has better earnings and valuation, BVXP or VRP?

Summary

How does Bioventix compare to Scancell?

Is BVXP or SCLP more profitable?

Does the media prefer BVXP or SCLP?

Which has more risk & volatility, BVXP or SCLP?

Do insiders & institutionals believe in BVXP or SCLP?

Which has better earnings & valuation, BVXP or SCLP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVXP vs. The Competition

Bioventix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools